Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Hls Therapeutics Inc (HLS.TO)

Hls Therapeutics Inc (HLS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 156,880
  • Shares Outstanding, K 31,886
  • Annual Sales, $ 63,074 K
  • Annual Income, $ -27,531 K
  • 60-Month Beta 1.01
  • Price/Sales 1.82
  • Price/Cash Flow 7.27
  • Price/Book 1.16
Trade HLS.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.85
  • Most Recent Earnings $-0.17 on N/A
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield 0.07 (4.07%)
  • Most Recent Dividend 0.050 on 04/27/23
  • Sectors:

    TSX Drug Specialty & Generic

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.23
  • Low Estimate -0.27
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -4.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.52 +40.62%
on 03/26/24
5.48 -9.67%
on 04/08/24
+0.90 (+22.22%)
since 03/19/24
3-Month
3.52 +40.62%
on 03/26/24
5.48 -9.67%
on 04/08/24
+0.90 (+22.22%)
since 01/19/24
52-Week
3.34 +48.20%
on 11/27/23
7.12 -30.48%
on 07/17/23
-1.05 (-17.50%)
since 04/19/23

Most Recent Stories

More News
Stocks in play: HLS Therapeutics Inc.

Announces that Chief Executive Officer Craig Millian will present at the Bloom Burton & Co. Healthcare ...

HLS.TO : 4.95 (+0.61%)
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

/CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 4.95 (+0.61%)
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

/CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

AMRN : 0.8593 (-1.43%)
HLS.TO : 4.95 (+0.61%)
HLS Therapeutics Announces Fiscal 2023 Financial Results

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

PFE : 26.00 (+2.40%)
HLS.TO : 4.95 (+0.61%)
HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2023 financial results on Thursday, March...

HLS.TO : 4.95 (+0.61%)
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 4.95 (+0.61%)
HLS Therapeutics Announces CFO Departure

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

VCM.TO : 22.05 (-1.96%)
HLS.TO : 4.95 (+0.61%)
New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 4.95 (+0.61%)
HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

PFE : 26.00 (+2.40%)
HLS.TO : 4.95 (+0.61%)
HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2023 financial results on Thursday, November 9,...

HLS.TO : 4.95 (+0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 4.95
2nd Resistance Point 4.95
1st Resistance Point 4.95
Last Price 4.95
1st Support Level 4.95
2nd Support Level 4.95
3rd Support Level 4.95

See More

52-Week High 7.12
Fibonacci 61.8% 5.68
Fibonacci 50% 5.23
Last Price 4.95
Fibonacci 38.2% 4.78
52-Week Low 3.34

See More

Business Summary

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar